Your browser doesn't support javascript.
loading
Structure-based design of free fatty acid receptor 1 agonists bearing non-biphenyl scaffold.
Li, Zheng; Chen, Yueming; Zhang, Yuhan; Jiang, Hongwei; Liu, Yanzhi; Chen, Yufang; Zhang, Luyong; Qian, Hai.
Afiliación
  • Li Z; School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou 510006, PR China; Center of Drug Discovery, State Key Laboratory of Natural Medicines, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing 210009, PR China.
  • Chen Y; School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou 510006, PR China.
  • Zhang Y; Center of Drug Discovery, State Key Laboratory of Natural Medicines, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing 210009, PR China.
  • Jiang H; School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou 510006, PR China.
  • Liu Y; School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou 510006, PR China.
  • Chen Y; School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou 510006, PR China.
  • Zhang L; School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou 510006, PR China; Guangzhou Key Laboratory of Construction and Application of New Drug Screening Model Systems, Guangdong Pharmaceutical University, Guangzhou 510006, PR China; Jiangsu Key Laboratory of Drug Screening, China Pharmace
  • Qian H; Center of Drug Discovery, State Key Laboratory of Natural Medicines, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing 210009, PR China; Jiangsu Key Laboratory of Drug Discovery for Metabolic Disease, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing 210009, PR China. Electronic addr
Bioorg Chem ; 80: 296-302, 2018 10.
Article en En | MEDLINE | ID: mdl-29980115
ABSTRACT
The free fatty acid receptor 1 (FFA1) enhances the glucose-stimulated insulin secretion without the risk of hypoglycemia. However, most of FFA1 agonists have a common biphenyl moiety, leading to a relative deprivation in structure types. Herein, we describe the exploration of non-biphenyl scaffold based on the co-crystal structure of FFA1 to increase additional interactions with the lateral residues, which led to the identification of lead compounds 3 and 9. In induced-fit docking study, compound 3 forms an edge-on interaction with Trp150 by slightly rotating the indole ring of Trp150, and compound 9 has additional hydrogen bond and δ-π interactions with Leu135, which demonstrated the feasibility of our design strategy. Moreover, lead compounds 3 and 9 revealed improved polar surface area compared to GW9508, and have considerable hypoglycemic effects in mice. This structure-based study might inspire us to design more promising FFA1 agonists by increasing additional interactions with the residues outside of binding pocket.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Diseño de Fármacos / Receptores Acoplados a Proteínas G / Hipoglucemiantes Límite: Animals / Humans / Male Idioma: En Revista: Bioorg Chem Año: 2018 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Diseño de Fármacos / Receptores Acoplados a Proteínas G / Hipoglucemiantes Límite: Animals / Humans / Male Idioma: En Revista: Bioorg Chem Año: 2018 Tipo del documento: Article